| 摘要 |
The present invention provides methods for inhibiting acute myeloid leukemia (AML) cells in a human diagnosed with AML or for treating AML, by administering a pharmaceutical composition comprising a human interleukin-3-diptheria toxin conjugate. The conjugate can be administered at a dose greater than 4 pg/kg to about 20 pg/kg. The conjugate may be a fusion protein comprising amino acids 1-388 of diphtheria toxin linked via a peptide bond to full-length, human interleukin-3. |
